- Home
- AYTU vs SILO Comparison
AYTU vs SILO Comparison
Compare AYTU & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- SILO
- Stock Information
- Founded
- AYTU N/A
- SILO 2010
- Country
- AYTU United States
- SILO United States
- Employees
- AYTU N/A
- SILO N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- AYTU Health Care
- SILO Consumer Discretionary
- Exchange
- AYTU Nasdaq
- SILO Nasdaq
- Market Cap
- AYTU 10.5M
- SILO 8.8M
- IPO Year
- AYTU N/A
- SILO N/A
- Fundamental
- Price
- AYTU $1.72
- SILO $1.87
- Analyst Decision
- AYTU
- SILO
- Analyst Count
- AYTU 0
- SILO 0
- Target Price
- AYTU N/A
- SILO N/A
- AVG Volume (30 Days)
- AYTU 27.9K
- SILO 9.0M
- Earning Date
- AYTU 02-12-2025
- SILO 02-14-2025
- Dividend Yield
- AYTU N/A
- SILO N/A
- EPS Growth
- AYTU N/A
- SILO N/A
- EPS
- AYTU N/A
- SILO N/A
- Revenue
- AYTU $79,759,000.00
- SILO $72,102.00
- Revenue This Year
- AYTU N/A
- SILO $1.86
- Revenue Next Year
- AYTU N/A
- SILO N/A
- P/E Ratio
- AYTU N/A
- SILO N/A
- Revenue Growth
- AYTU N/A
- SILO N/A
- 52 Week Low
- AYTU $1.30
- SILO $0.77
- 52 Week High
- AYTU $3.45
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- AYTU 54.22
- SILO 73.43
- Support Level
- AYTU $1.68
- SILO $1.62
- Resistance Level
- AYTU $1.93
- SILO $2.07
- Average True Range (ATR)
- AYTU 0.12
- SILO 0.33
- MACD
- AYTU 0.00
- SILO 0.07
- Stochastic Oscillator
- AYTU 36.36
- SILO 39.76
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.